Close Menu

NEW YORK – The Blood Profiling Atlas in Cancer Consortium (BloodPAC) has released a series of analytical protocols for validating next-generation sequencing (NGS)-based circulating tumor DNA (ctDNA) assays, which the consortium believes will help accelerate the development and regulatory reviews of new tests.

Developed by consortium members, the resource may potentially serve as a set of generic analytical protocols and help to define industry standards for developing liquid biopsy assays.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.